Australian biopharma CSL announced a strategic overhaul involving the separation of its influenza vaccine business, Seqirus, into a standalone company projected to be completed by June next year. The restructuring includes workforce reductions of up to 15%, aiming to save over $500 million annually. Despite modest revenue growth in the vaccine unit, the company cited market softness and competitive pressures as challenges. CEO Paul McKenzie acknowledged disappointing U.S. seasonal influenza vaccine uptake despite severe disease burden. The spin-off and cost-cutting efforts seek to enhance pipeline productivity and focus on priority programs.